Journal of Experimental Therapeutics and Oncology最新文献_第7页

Calcifying epithelial odontogenic cyst. 钙化上皮性牙源性囊肿。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-11-01

Balaji Manohar, Dhritiman Baidya, Neema Shetty, Aditi Mathur, Barkha Makhijani

{"title":"Calcifying epithelial odontogenic cyst.","authors":"Balaji Manohar, Dhritiman Baidya, Neema Shetty, Aditi Mathur, Barkha Makhijani","doi":"","DOIUrl":"","url":null,"abstract":"Objective: The Calcifying Odontogenic Cyst was first described as a distinct clinicopathologic entity by Gorlin and his colleagues in 1962. Gold (1963) chose a similar, but not identical term for the lesion, namely 'keratinizing and calcifying odontogenic cyst'. The calcifying cystic odontogenic tumor (CCOT) is a new designation of calcifying odontogenic cyst (COC) recommended by the 2005 classification of the World Health Organization (WHO). The calcifying odontogenic cyst is not a common lesion; the dentinogenic ghost cell tumor is even less common and should be considered rare. The lesions have in common the peculiar abnormal keratinization of odontogenic and metrical (hair) epithelial cells that is termed 'ghost cell' or 'shadow cell' keratinization. A rare, well-circumscribed, solid or cystic lesion derived from odontogenic epithelium that resembles follicular ameloblastoma but contains 'ghost cells' and spherical calcifications. The so-called calcifying odontogenic cyst (COC) represents a heterogeneous group of lesions that exhibit a variety of clinicopathologic and behavioural features. Because of this diversity, there has been confusion and disagreement on the terminology and classification of these lesions. Here we present a classic case of Calcifying Odontogenic Cyst (COC) or Calcifying Cystic Odontogenic Tumor in a 37 years old male patient. which is provisionally diagnosed by means of clinical & radiographical findings and later on confirmed by histological examination.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35573609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In silico docking studies of Lupeol with MAPK pathway proteins- Raf-1, MEK & ERK. Lupeol与MAPK通路蛋白- Raf-1, MEK和ERK的硅对接研究。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-11-01

Mital H Bhatt, Chirag K Prajapati, M N Reddy

{"title":"In silico docking studies of Lupeol with MAPK pathway proteins- Raf-1, MEK & ERK.","authors":"Mital H Bhatt, Chirag K Prajapati, M N Reddy","doi":"","DOIUrl":"","url":null,"abstract":"Objective: Lupeol, A triterpenoid found in variety of plants is reported to have beneficial medicinal effects on several ailments. Lupeol is also found to show inhibitory effect on proliferation of breast cancer cells. Metastasis is considered to be a major cause for worldwide deaths related to cancer. Ras related MAPK Signaling Pathway is one of the crucial pathways leading to metastasis. Lupeols binding possibility with Ras is already reported. In present study, Interaction between with downstream proteins of Ras- MAPK pathway, Raf ,MEK ,ERK1/2 and their corresponding domains are studied using STRING Database and their structures are retrieved in PDB Format. Lupeols binding affinity with downstream proteins of these signaling proteins at their interacting domains are analyzed. Here in silico docking approach to identify binding sites of each of these proteins with Lupeol is used. FDA approved standard drug molecule CH5126766 was used as reference ligand. Lupeol shows potent binding at significant sites with extremely high affinity. Since it binds with all the proteins involved in the pathway with high efficiency it is an important compound which can be developed as a therapeutic molecule.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35627070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer Control Algorithm. 癌症控制算法。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-11-01

Sunil Kumar Kashyap, Birendra Kumar Sharma, Amitabh Banerjee

引用次数: 0

Effect of lupeol on antioxidants and xenobiotic enzymes in N-Butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats. 鹿皮醇对n -丁基- n -(4-羟基丁基)亚硝胺诱导大鼠膀胱癌抗氧化剂和外生酶的影响。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Bhoopathy Prabhu, Annamalai Sivakumar, Doraisami Balakrishnan, Sivapatham Sundaresan

{"title":"Effect of lupeol on antioxidants and xenobiotic enzymes in N-Butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.","authors":"Bhoopathy Prabhu, Annamalai Sivakumar, Doraisami Balakrishnan, Sivapatham Sundaresan","doi":"","DOIUrl":"","url":null,"abstract":"Objective: Urothelial carcinoma of the bladder is a common malignancy ranked 9th with an estimated 356,600 new cases diagnosed annually worldwide. The study showed the protective effects of Lupeol in N-Butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in in vivo experimental model. Forty male healthy wistar rats were selected randomly divided into four groups. Group I rats served as healthy control. Group II rats were treated with BBN (150 mg/gavage/twice a week) for 8 weeks. Group III rats were treated with BBN + Lupeol [ Lupeol (50 mg/kg bw/day) treatment was started 1 week prior to the BBN treatment, and it was orally administered for 8 weeks]. Group IV rats were treated with Lupeol alone (50 mg/kg bw/day) for 8 weeks. All the experimental rats were maintained and euthanized at 32nd week. Serum and bladder tissues were collected and examined for biochemical parameters, serum markers and histopathological evaluation. Preventive (BBN + Lupeol) group modulates the activity of antioxidant enzymes such as Superoxide dismutase, Catalase, Reduced glutathione, Glutathione Peroxidase, Thiobarbituric acid reactive substances (TBARS) and drug metabolizing enzymes such as Cytochrome P450, Cytochrome b5, NADPH Cytochrome c reductase, NADPH- Quinone Oxidoreductase 1 and Glutathione-S-transferase when compared to BBN treated rats. Serological markers such as Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) were significantly (P&#60;0.05) decreased in preventive lupeol treated groups. Lupeol supplementation protects BBN induced bladder carcinogenesis in experimental rats by its antioxidant, anti-inflammatory and antiproliferative properties.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35414769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiotensin receptor signaling and prostate tumor growth in mice. 血管紧张素受体信号传导与小鼠前列腺肿瘤生长。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Jem Scott-Emuakpor, Emma Allot, Stacy A Johnson, Lauren E Howard, Everardo Macias, Stephen J Freedland, Susan B Gurley

{"title":"Angiotensin receptor signaling and prostate tumor growth in mice.","authors":"Jem Scott-Emuakpor, Emma Allot, Stacy A Johnson, Lauren E Howard, Everardo Macias, Stephen J Freedland, Susan B Gurley","doi":"","DOIUrl":"","url":null,"abstract":"Objective: The renin-angiotensin system, through its type 1 and type 2 angiotensin receptors (AT1R and AT2R, respectively) may have a role in prostate cancer. The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. We also evaluated the tumor growth effects of using angiotensin II to activate both AT1R and AT2R simultaneously. Our data showed that losartan decreased tumor volumes by 56% versus control. This decrease reached statistical significance at day 54 (p = 0.0014). By day 54, Ki67 was also reduced in the losartan group, though not significantly so (p = 0.077). Losartan had no significant effect on AT1R or AT2R expression. Despite significant increases in both AT1R and AT2R at day 29 (p = 0.043 and 0.038, respectively), the administration of angiotensin II did not result in any significant differences in tumor volumes or ki67 at any time point. These data suggest that selective activation and induction of AT2R coupled with blockade of AT1R may slow prostate cancer growth. Future larger studies are needed to confirm these results.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311706/pdf/nihms-999417.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35467703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipoma of round ligament on the intraperitoneal portion (abdominal site): a case report. 腹腔内圆形韧带脂肪瘤1例。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Ozhan Ozdemır, Mustafa Erkan Sarı, Vefa Selimova Sakar, Mehriban Nebıoglu, Cemal Resat Atalay

引用次数: 0

Poly-MVA attenuates 7,12- dimethylbenz[a]anthracene initiated and croton oil promoted skin papilloma formation on mice skin. 聚mva可减弱7,12-二甲基苯[a]蒽引起的皮肤乳头瘤形成，而巴豆油可促进皮肤乳头瘤形成。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Ravindran K Veena, Thekkuttuparambil A Ajith, Kainoor K Janardhanan, Francis Antonawich

{"title":"Poly-MVA attenuates 7,12- dimethylbenz[a]anthracene initiated and croton oil promoted skin papilloma formation on mice skin.","authors":"Ravindran K Veena, Thekkuttuparambil A Ajith, Kainoor K Janardhanan, Francis Antonawich","doi":"","DOIUrl":"","url":null,"abstract":"Objective: Chemopreventive agents which exhibit activities such as anti-inflammation, inhibition of carcinogen induced mutagenesis and scavenging of free radical might play a decisive role in the inhibition of chemical carcinogenesis either at the initiation or promotion stage. Many synthesized palladium (Pd) complexes tested experimentally for antitumor activity are found effective. Poly-MVA is a liquid blend preparation containing B complex vitamins, ruthenium with Pd complexed with alpha lipoic acid as the major ingredients. The antitumor effect of Poly-MVA was evaluated against 7,12-dimethylbenz[a] anthracene-initiated croton oil-promoted papilloma formation on mice skin. Skin tumor was initiated with a single application of 390 nmol of DMBA in 20 µl acetone. The effect of Poly-MVA against croton oil- induced inflammation and lipid peroxidation on the mice skin was also evaluated. Topical application of Poly-MVA (100 µl, twice weekly for 18 weeks) 30 minutes prior to each croton oil application, significantly decreased the tumor incidence (11%) and the average number of tumor per animals. Application of Poly-MVA (100 µl) before croton oil significantly (p &#60; 0.05) protected the mouse skin from inflammation (36%) and lipid peroxidation (14%) when compared to the croton oil alone treated group. Experimental results indicate that Poly-MVA attenuate the tumor promoting effects of croton oil and the effect may probably be due to its anti-inflammatory and antioxidant activity.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35414205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leiomyosarcoma of maxilla: a case report with review of literature. 上颌骨平滑肌肉瘤1例并文献复习。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Renuka Gupta, Madhusudan Astekar, Ramakant Dandriyal, Manjunath Bs

引用次数: 0

Tumor protein 53 mutations mapping to its tertiary structure with in-silico prediction of neoepitopic vaccine candidates in bone tumors. 肿瘤蛋白53突变定位到其三级结构与骨肿瘤新表位候选疫苗的计算机预测。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Hamid Nawaz Tipu, Abdul Rehman Arshad

引用次数: 0

Chronic subdural hematoma following spinal anesthesia for cesarean section. 剖宫产腰麻术后慢性硬膜下血肿。

Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01

Kübra Mehel Metin, Is Il Güzel, Aslı Oskovi, Ali Irfan Guzel

引用次数: 0